What 'research use only' is supposed to signal
A research-use-only label does not protect a product promoted for clinical use. Ask counsel to evaluate the actual product, distribution and marketing.
For perinatal-derived biologics, a supplier's research-use-only designation, where one is applied, only holds up if everything downstream of the label treats the product as research material: the catalog listing, the sales conversation, and the invoice, not just the printed label itself.
Why FDA looks past the label to the marketing
FDA has stated that it treats a product's intended use as something shown by the totality of evidence, including labeling, advertising, and the circumstances of distribution. A label stating "research use only" does not control that analysis if other evidence points to clinical use.
The 2026 warning letters referenced below made this concrete: FDA treated promotional content on company websites and social media as controlling, not the label text.
What the pattern in the 2026 warning letters shows
Across the three warning letters referenced in this library, R3 Medical Companies on August 14, Blue Horizon International on May 26, and Dynamic Stem Cell Therapy on February 11, the common thread was marketing content describing disease-related or clinical use on company websites and social media, reviewed by FDA as evidence of intended use.
The throughline across all three is that this evidence was evaluated independently of whatever label or disclaimer language may have appeared elsewhere on the same site or on the product packaging.
What this means for a distributor relationship
A clinic buying from a distributor should ask directly how that distributor's own marketing describes the product, since that marketing becomes part of the regulatory picture for everyone in the supply chain who repeats it, not only for the distributor itself.
It also means a clinic's own internal purchasing file should separate "what the product is" documentation (certificate of analysis, donor eligibility summary, processing description) from any marketing claims, and should not treat a supplier's research-use-only or similar label as a substitute for its own counsel's read of the product's status.
What this does not mean
This article does not determine whether any purchase or use is lawful; review that question with regulatory counsel.
A label alone, in either direction, does not resolve the underlying regulatory question. That question is specific to the product, its processing, its claimed category, and how it is actually marketed, and it belongs with FDA regulatory counsel rather than with disclaimer text.
Frequently asked questions
If a supplier labels a product research use only, can clinics use it clinically anyway?+
Labeling and actual use are separate questions. Whether a given use is appropriate for a specific product is a determination for the clinic and its own regulatory counsel, independent of how the supplier labeled the product.
Does adding a disclaimer to our own marketing fix a disease claim elsewhere on the same page?+
No. FDA's review looks at the overall impression created by the content, and a disclaimer does not offset a disease or outcome claim made elsewhere.
Why does FDA look at social media instead of just the printed label?+
Because FDA's framework for intended use considers the totality of evidence, including advertising and the circumstances of distribution, not only label text.
What should we ask a supplier about research-use-only claims before ordering?+
Ask how the label matches the supplier's own marketing and catalog language, and ask for the documentation (certificate of analysis, donor eligibility summary) that supports whatever category the supplier claims, then review that answer with your own counsel.
Sources
- Patient and consumer warning about potential serious risks following use of unapproved products ↗FDA
- Warning letter: R3 Medical Companies (CBER 26-726330, Aug 14 2026) ↗FDA
- Warning letter: Blue Horizon International LLC (CBER 26-728085, May 26 2026) ↗FDA
- Warning letter: Dynamic Stem Cell Therapy (Feb 11 2026) ↗FDA